Cohort Study | 5-year outcomes after stereotactic ablative body radiotherapy for primary renal cell carcinoma

5-year outcomes after stereotactic ablative body radiotherapy for primary renal cell carcinoma: an individual patient data meta-analysis from IROCK (the International Radiosurgery Consortium of the Kidney) – The Lancet Oncology (link to abstract – $ for full-text)

Commentary from the author on Twitter (thread – click for more)

?1/ Wide adoption of SABR for primary #kidneycancer is limited by long-term data. Online today @TheLancetOncol; 5-yr outcomes in 190 patients. 5% local failure rates, 95% cancer-specific survival. Thanks @ElsevierConnect for 50-day link: #radonc #kcsm https://t.co/kCM8TraJE3

— Shankar Siva (@_ShankarSiva) November 16, 2022